The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines by Pamela Viani de Andrade et al.
de Andrade et al. Cancer Cell Int  (2016) 16:31 
DOI 10.1186/s12935-016-0306-5
PRIMARY RESEARCH
The histone deacetylase inhibitor 
PCI-24781 as a putative radiosensitizer 
in pediatric glioblastoma cell lines
Pamela Viani de Andrade1, Augusto Faria Andrade2, Rosane Gomes de Paula Queiroz1, Carlos Alberto Scrideli1, 
Luiz Gonzaga Tone1,2 and Elvis Terci Valera1*
Abstract 
Background: Glioblastoma (GBM) is considered to be one of the most aggressive tumors of the central nervous sys-
tem (CNS). Even with the use of modern treatment protocols, the prognosis remains reserved, with children with GBM 
having a mean survival of 12–15 months.
Methods: In the present study we investigated the potential radiosensitizing effect of PCI-24781, a potent pan-
histone deacetylase inhibitor (HDACi), on the SF188 and KNS42 cell lines of pediatric GBM. Cell proliferation rates, 
clonogenicity and apoptosis were compared in the presence and absence of treatment with PCI-24781. We also com-
pared the clonogenicity rates of the irradiated SF188 and KNS42 cell lines with or without previous treatment with 
PCI-24781 at the doses of 0.25–16 μM. In addition, we investigated the effects of PCI-24781 on the expression of some 
of the main proteins responsible for the repair of double-strand DNA breaks caused by irradiation.
Results: The inhibitor blocked cell proliferation, induced death by apoptosis and reduced the colony forming 
capacity of the cell lines, both of them showing a significant decrease of colony formation at all irradiation doses. 
The expression of the Rad51 protein, important for the homologous recombination (HR) repair pathway, and of the 
DNA-PKcs, Ku70 and Ku86 proteins, important for the non-homologous end joining (NHEJ) repair pathway, was more 
reduced when the irradiated cell line was previously treated with PCI-24781 than when it was treated exclusively with 
radiotherapy.
Conclusions: These findings demonstrate that HDACi PCI-24781 has a radiosensitizing profile that compromises the 
repair of double-strand DNA breaks in cells of pediatric GBM treated with radiotherapy.
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Background
Glioblastoma (GBM) is considered to be the most aggres-
sive and most frequent central nervous system (CNS) 
tumor among adults, representing about 65  % of cases 
[1] in this population. In children, this is a relatively 
rare, although also very aggressive tumor, representing 
approximately 3 % of all childhood CNS neoplasms. Due 
to this low incidence, studies about pediatric GBM are 
less frequent than studies on adults [2].
The treatment strategy for GBM has not changed sub-
stantially over the last few years and essentially consists of 
surgical resection, radiotherapy and chemotherapy. Chem-
otherapy is usually employed to inhibit the replication of 
tumor clones or to provoke DNA damage in order to induce 
cell apoptosis [3, 4]. This multimodal therapy has been used 
as a standard treatment protocol for most patients, although 
survival continues to be low [5]. Five-year survival is reached 
by only 10 % of pediatric patients with GBM [6].
Temozolomide is the chemotherapeutic agent most 
frequently used for the treatment of adults and children 
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with GBM but has been found to be poorly effective for 
the treatment of pediatric patients [7–9]. In addition to 
chemotherapy, radiotherapy is used for treatment after 
surgical resection in children older than 3 years. In chil-
dren younger than 3 years, adjuvant chemotherapy is fre-
quently used in an attempt to postpone or even to avoid 
radiotherapy [10]. However, both chemotherapy and 
radiotherapy are potentially toxic and contribute to sig-
nificant morbidity and mortality [11].
Radiotherapy induces various types of DNA dam-
age, among them double-strand breaks (DSB). DSB 
are defined as two simultaneous breaks in the opposite 
strands of the DNA helix. Although the cells are able 
to adapt to low levels of irreparable DNA damage, only 
one DSB is already potentially cytotoxic and can induce 
apoptosis in certain cell types [12–14]. The response of 
normal cells to DSBs includes the detection and repair 
of these radioinduced injuries by proteins sensing DNA 
damage and by DNA repair proteins, respectively. DSB 
repair in DNA occurs through two important repair 
pathways. One is homologous recombination (HR), 
which is the more precise mechanism of DSB repair and 
whose absence can lead to extensive genomic rearrange-
ments and consequently to genomic instability. In HR, a 
homologous DNA sequence in a sister chromatid is used 
as a model for the repair of the broken strand [15]. The 
other is repair by nonhomologous end joining (NHEJ), 
which is a less precise form of DSB repair since the two 
endings of the broken DNA molecule are processed in 
order to form compatible endings that will be directly 
bound without being based on an undamaged DNA mol-
ecule. This mechanism is subject to a higher occurrence 
of errors since it does not require sequence homology 
for repair to occur, with the possible occurrence of small 
deletions or insertions [16].
New treatment strategies have been recently explored 
for gliomas, such as drug and therapy combinations 
directed at the molecular characteristics and genomic 
profile of the patients [17]. These studies include drugs 
that control epigenetic changes, which are of consider-
able interest as targets for cancer treatment because of 
their vital function in the cell processes that lead to onco-
genesis [18]. The main epigenetic mechanisms explored 
in brain tumors are DNA methylation, the action of small 
noncoded RNAs and the modifications of histone pro-
teins which determine the structure and activity of dif-
ferent chromatin regions and which are involved in cell 
memory and identity [19–22].
Among the various types of histone modifications, 
acetylation is the one that has been best characterized 
and that plays an important role in the modulation of the 
expression of genes that act on cell cycle control and con-
tribute to the development and progression of neoplasia 
[20, 23–26]. Histone acetylation is performed by enzymes 
called histone acetyltransferases (HATs) which add acetyl 
radicals to the lysine residues of histone proteins, result-
ing in chromatin decompaction and transcriptional activ-
ity. On the other hand, histone deacetylases (HDACs) act 
by removing acetyl radicals and by recruiting corepressor 
complexes, resulting in chromatin compaction and gene 
silencing [23, 27, 28].
The objective of the present study was to assess the 
therapeutic potential of the HDAC inhibitor PCI-24781 
against the pediatric GBM cell lines SF188 and KNS42, 
by analyzing the rates of cell proliferation, the clonogenic 
capacity and the apoptosis rates. We also investigated the 
effects of PCI-24781 as a possible radiosensitizing agent 
on both GBM lines by analyzing the clonogenic capac-
ity and potential of the drug in changing the expression 
of proteins involved in the repair of double-strand DNA 
breaks caused by irradiation, i.e., Rad51, the heterodimer 
Ku70/Ku86 and DNA-PKcs.
Methods
Cell lines and culture conditions
The pediatric GBM lines SF188 (kindly provided by 
Dr. Nada Jabado and Dr. Damien Faury—McGill Univer-
sity—Canada) and KNS42 (obtained from the Japanese 
Collection of Research Bioresources Cell Bank through 
the Cell Bank of Rio de Janeiro) were used in the present 
study. The SF188 cell line was cultured in 75  cm2 bot-
tles using HAM F10 culture medium supplemented with 
60  mg/L penicillin, 100  mg/mL streptomycin and 10  % 
(v/v) fetal calf serum (FCS; Gibco BRL, Life Technologies, 
Carlsbad, CA, USA), pH 7.2–7.4, in a moist atmosphere 
containing 5  % CO2 at 37  °C. The KNS42 cell line was 
cultured in MEM medium supplemented with 60  mg/L 
penicillin, 100  mg/mL streptomycin and 5  % (v/v) FCS 
(Gibco BRL, Life Technologies), pH 7.2–7.4, in a moist 
atmosphere containing 5 % CO2 at 37 °C. The SF188 line 
originated from an 8-year-old male patient, has a TP53 
mutation in codon 266 [GGA(Gly)/GAA(Glu)], and 
is not tumorigenic. The KNS42 line originated from a 
16-year-old male patient with primary GBM located in 
the right frontoparietal lobe and has a TP53 mutation in 
codon 342[GGA(Arg)/TGA(Stop)] [29].
Histone deacetylase inhibitor and treatments
According to the literature and to pilot experiments per-
formed, a stock solution of the histone deacetylase inhib-
itor PCI-24781 (Selleckchem, Houston, TX, USA) was 
prepared at a final concentration of 50 mM in dimethyl-
sulfoxide (DMSO; Mallinckrodt Chemical Works, St 
Louis, MO, USA) and stored in aliquots at −80 °C. Work-
ing solutions of 10 mM were prepared also in DMSO and 
stored in aliquots at −80 °C.
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The drug was added to the culture medium and 
homogenized before being added to the cell culture. The 
DMSO concentration was 0.1  %. All controls were nor-
malized by adding the same amount of DMSO as used 
for the treated cells.
Cell proliferation assay
Cell proliferation was determined by the assay using the 
Resazurin Cell Viability kit according to manufacturer 
instructions. A total number of 2 × 103 cells were seeded 
in 96-well plates and kept under culture conditions for 
24 h. Next, the cells were treated with HDACi at the con-
centrations of 0.5, 1, 2, 4, 8 and 16 µM and incubated for 
24, 48, 72 and 96 h. A resazurin solution was added to the 
plate (10 % of the initial volume in the well) at each treat-
ment interval. The plates were incubated for 4  h under 
standard culture conditions. The non-fluorescent blue 
reagent is reduced to highly fluorescent resorufin by the 
dehydrogenase enzymes present in metabolically active 
cells with an absorbance peak at 570  nm. Absorbance 
readings were taken with the iMax Microplate Reader 
(Bio-Rad, Hercules, CA, USA), with the value detected 
being proportional to the quantity of cells in prolifera-
tion. These data were used to obtain the IC50 and IC30 
values, which are defined as the concentrations necessary 
for a 50 and 30 % reduction of proliferation, respectively, 
using the Calcusyn software (Biosoft, Ferguson, MO, 
USA). Three independent experiments were performed 
in triplicate.
Apoptosis assay
The assay for the detection of cell death was carried out 
by labeling apoptotic cells with annexin V fluorescein 
isothiocyanate (BD Biosciences Pharmigen, San Jose, 
CA, USA) and necrotic cells with propidium iodide (PI). 
Annexin V is a molecule with high affinity for phosphati-
dyl serine, to which it binds specifically. Phosphatidyl 
serine is a phospholipid present on the inner surface of 
the cell membrane which is externalized during the pro-
cess of apoptosis and acts as a signal for the cells to be 
removed. Labeling with PI indicates that cells have lost 
their membrane integrity.
After a 48 h treatment at concentrations of 2, 4, 8 and 
16 µM of the PCI-24781 inhibitor, the cells were trypsi-
nized, centrifuged at 1000 r.p.m. for 5 min, washed with 
ice-cold 1 X PBS and resuspended in 300 μL 1 X annexin 
V binding buffer (BD Biosciences Pharmingen, San Jose, 
CA, USA). The cells were then labeled with 5 μL annexin 
V and 50 μL of a 50 μM PI solution, and analyzed with a 
BD FACSCalibur™ flow cytometer (BD Biosciences Phar-
migen) for a total of 10,000 events per treatment. The val-
ues represent the mean and standard deviation of three 
independent experiments performed in triplicate.
Clonogenic assay
The effect of the PCI-24781 inhibitor on clonogenic 
capacity was assessed according to the protocol of 
Franken et  al. [30]. Cell suspensions of the SF188 and 
KNS42 lines were seeded at a density of 300 cells/well on 
six-well plates. After 24  h of incubation, the cells were 
treated with PCI-24781 concentrations of 0.25, 0.5, 1 and 
2 µM and incubated in an oven at 37  °C for 48 h. Next, 
the culture medium was removed, the cells were washed 
with 1 X PBS, and drug-free medium was added in order 
to permit colony growth for approximately 7–10  days 
at 37  °C. After this period, the culture medium was 
removed, the cells were washed with PBS, fixed in abso-
lute methanol and stained with 1 % Giemsa. Colonies of 
at least 50 cells were counted with a magnifying glass.
IC30 values, defined as the concentration necessary for 
a 30 % reduction of cell proliferation calculated with the 
Calcusyn software (Biosoft, Ferguson, MO, USA), were 
used for the assay combining the inhibitor with radio-
therapy. The cells were then seeded as described earlier 
and treated with PCI-24781 for 48 h. Next, the cells were 
washed with 1X PBS and drug-free medium was added 
before irradiation with an RS-2000 X-Ray Irradiator Bio-
logical System (Rad Source Technologies, Inc., Suwanee, 
USA). The irradiation rate was 1115  Gy/min and the 
doses were 0, 0.5, 1, 2 and 4 Gy. The irradiated cells were 
then incubated at 37  °C for 7–10 days, fixed in absolute 
methanol, stained with Giemsa, and counted. The values 
represent the mean and standard deviation of three inde-
pendent experiments carried out in triplicate.
Protein expression—western blotting
Protein extraction
Total protein extraction was performed using RIPA® 
lysis buffer (Sigma Aldrich Co., Saint Louis, MO, USA) 
together with protease and phosphatase inhibitors 
according to manufacturer instructions. Protein concen-
tration was then determined by the method of Bradford, 
1976 [31] using bovine serum albumin (BSA, 0.1 mg/mL) 
as standard. Absorbance readings at 595 nm wavelength 
were obtained with an iMax Microplate Reader spectro-
photometer (Bio-Rad Laboratories Inc., CA, USA).
Western blotting
The methodology proposed by Sambrook et  al. 1989 
[32] was modified as described below. Equal concentra-
tions (60  μg) of total proteins were submitted to 10  % 
polyacrylamide SDS gel electrophoresis using the Mini 
Protean II Dual Slab Cell system (Bio-Rad, USA). After 
transfer to a nitrocellulose membrane, the immunode-
tection process was started by blocking the membranes 
in a 5 % non-fat milk solution in 0.1 % TBST for one h. 
Next, the membranes were incubated overnight with the 
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specific primary antibodies for each protein and then 
with anti-GAPDH and anti-β-actin (Santa Cruz Biotech-
nology, USA) for 1 h. The membranes were then washed 
with TBST (five washes of 5  min each), incubated with 
the appropriate horseradish peroxidase-conjugated sec-
ondary antibody and submitted to an additional wash 
cycle. The reaction was developed using the chemilumi-
nescent substrate ECLTM (Amersham GE Healthcare, 
Buckinghamshire, UK) and visualized with the Chemi-
DOC XRS instrument (Bio-Rad, USA).
Statistical analysis
All assays were carried out in triplicate and in three inde-
pendent experiments. The mean and standard deviation 
of the experiments was considered for analysis by one-
way ANOVA and two-way ANOVA followed by the non-
parametric Bonferroni test.
The effect of the HDACi PCI-2478 on the combination 
and the effect of the irradiation dose on percent colony 
numbers was tested by logistic regression.
All analyses were performed with the aid of the SPSS 
20.0 software (SPSS, Chicago, IL, USA), with the level of 
significance set at p < 0.05.
Percent cell proliferation, clonogenic survival, radio-
sensitization and apoptosis are presented graphically in 
the form of histograms using the GraphPad Prism soft-
ware, version 5.0. Protein quantitation was performed 
using the Image J software, version1.49t (Research 
Services Branch, National Institute of Mental Health, 
Bethesda, MD, USA).
Results
Effects of the PCI‑24781 inhibitor on cell proliferation
We first investigated the effect of PCI-24781 on cell pro-
liferation at doses of 0.5, 1, 2, 4, 8 and 16 µM for periods 
of 24, 48, 72 and 96 h on the cell lines SF188 and KNS42. 
A significant growth inhibition (p  <  0.05) was detected 
compared to control at 48 and 96 h of treatment starting 
with the 2 µM dose. For the 72 h time point, this inhibi-
tion occurred starting with the 4 µM dose. After 24 h of 
exposure, the only dose that significantly reduced prolif-
eration compared to control was 8  µM (Fig.  1). For the 
KNS42 line, a significant growth inhibition (p  <  0.05) 
compared to control was observed at the doses of 2, 4, 8 
and 16 µM at the 48 and 72 h time points and at the 96 h 
time point starting with the 1 µM dose, There was no sig-
nificant inhibition at the 24 h time point (Fig. 2).
Effects of the PCI‑24781 inhibitor on the induction 
of apoptosis
We next investigated whether the reduction of cell pro-
liferation observed was due to cell death by apoptosis. 
In order to determine if PCI-24781 induced apoptosis in 
cell lines of pediatric GBM we determined the percent-
age of apoptotic cells after labeling with annexin-V and 
propidium iodide (PI). Apoptosis was induced at 48  h 
at the doses of 2, 4, 8 and 16 µM in the pediatric GBM 
lines SF188 and KNS42. All doses tested showed a sig-
nificant effect of increased apoptosis compared to control 
(p < 0.05). Starting at the 2 µM dose, the effect on the cell 
death rate of both lines was already quite significant com-
pared to control, demonstrating that only a small dose 
of the PCI-24781 inhibitor was able to induce apoptosis. 
The cell death rate by apoptosis was almost 40 % for the 
SF188 line and 55 % for the KNS42 line at the maximum 
dose tested (Fig. 3).
Effects of the PCI‑24781 inhibitor on clonogenic capacity
In order to determine whether the reduction of prolifera-
tion affected cell growth in the long term and to test the 
capacity of tumor renewal, the test of clonogenic capacity 
Fig. 1 Analysis of cell proliferation of the SF188 line after treatment 
with PCI-24781. *p < 0.05 for treated cells compared to control
Fig. 2 Analysis of cell proliferation of the KNS42 line after treatment 
with PCI-24781. *p < 0.05 for treated cells compared to control
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was performed at the 48 h time point at the doses of 0.25, 
0.5, 1 and 2  µM on the pediatric GBM lines SF188 and 
KNS42. The analysis revealed that all doses induced a 
significant fall in colony formation compared to con-
trol (p  <  0.001). The SF188 line exhibited a reduction 
of colony formation of almost 99 % and the KNS42 line 
was unable to form colonies at the maximum dose used 
(Fig. 4).
Radiosensitizing effect of the PCI‑24781 inhibitor 
on clonogenic capacity
In order to determine the radiosensitizing effect of PCI-
24781, the SF188 and KNS42 lines were treated with 
IC30 of the inhibitor, which was 0.25 µM for SF188 and 
0.15 µM for KNS42, in combination with radiation at the 
doses of 0.5, 1, 2 and 4 Gy. It was observed that treatment 
with the inhibitor radiosensitized both cell lines, with a 
greater effect on the KNS42 line. The SF188 line showed 
a practically absent reduction of colony formation in the 
treatment with irradiation alone and a 45  % reduction 
with the combined treatment with PCI-24781 and the 
highest irradiation dose (Fig. 5). The KNS42 line showed 
a 20  % reduction of colony formation with irradiation 
alone and a 70 % reduction with the combined treatment 
with PCI-24781 and the highest irradiation dose (Fig. 6). 
Thus, treatment with PCI-24781 was able to sensitize 
strongly both lines to radiation.
Fig. 3 Percentage of annexin V-positive cells after treatment with 
PCI-24781 in the SF188 and KNS42 lines. *p < 0.05 for treated cells 
compared to control
Fig. 4 Percentage of colonies after treatment with PCI-24781 in 
the SF188 and KNS42 lines. *p < 0.001 for treated cells compared to 
control
Fig. 5 PCI-24781 radiosensitizes the SF188 line. *p < 0.001. Data are 
reported as the mean ± standard deviation of three independent 
experiments. p values obtained by linear regression are shown for all 
cell lines (DMSO versus PCI-24781)
Fig. 6 PCI-24781 radiosensitizes the KNS42 line. *p < 0.001. Data are 
reported as the mean ± standard deviation of three independent 
experiments. p values obtained by linear regression are shown for all 
cell lines (DMSO versus PCI-24781)
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Effect of the PCI‑24781 inhibitor on the expression 
of proteins responsible for the repair of double‑strand 
DNA breaks
Western-Blot was used to determine the ability of the 
PCI-24781 agent to change the expression of some pro-
teins present in the major pathways responsible for the 
repair of the DSB induced by irradiation: the RAD51 
protein, important for the HR pathway, the Ku70/Ku86 
heterodimer and the DNA-PKcs protein, important for 
NHEJ. For the analysis, we used the IC30 value (0.25 µM) 
of PCI-24782 for the SF188 line for 48 h and irradiation 
doses of 4 and 6 Gy. The proteins were collected after 4 h 
of exposure to irradiation.
The results showed that PCI-24781 was competent in 
reducing the efficiency of the SF188 line in diminishing 
the DSB induced by irradiation, with a reduction of the 
expression of the proteins tested. For the Ku 70, Ku 86 
and DNA-PKcs proteins there was only a small difference 
between treatment with PCI-24781 alone or in combi-
nation (Figs.  7, 8, and 9 respectively). The most evident 
decrease was observed for the RAD51 protein, present 
in the HR pathway. For all proteins, treatment with PCI-
24781 followed by 6 Gy of irradiation demonstrated the 
greatest inhibition of the repair pathway (Fig. 10).   
Discussion
Over the last few years, the association between HDACs 
and carcinogenesis has increased the interest in the use 
of HDACi as antitumor agents. HDACi are new anti-
cancer agents that induce tumor cell death and differen-
tiation, chromatin decondensation and arrest of the cell 
cycle [33].
Uncontrolled cell proliferation is a strong characteris-
tic of aggressive tumors, including GBM [34]. In the pre-
sent study, the PCI-24781 inhibitor was found to cause 
efficient inhibition of cell proliferation and increased 
cell death by apoptosis in both the SF188 and KNS42 
cell lines. Similar effects of inhibition of proliferation 
and induction of apoptosis have been reported in the 
literature for PCI-24781 and other HDACi, in separate 
treatments or in combination with other agents against 
neoplastic cell lines [35–40]. Some in  vivo experiments 
have also been reported in the literature with the objec-
tive of investigating the possible mechanisms involved 
in the therapeutic effect of the HDACi PCI-24781 in the 
inhibition of cell proliferation in mice and on patient-
derived xenografts [41, 42].
Both lines studied herein here have a mutation of the 
TP53 gene, but several studies have demonstrated no 
Fig. 7 PCI-24781 alters the expression of the Ku70 protein. a PCI-24781 reduces the expression of the Ku70 protein, important for the repair of 
double-strand breaks caused by irradiation through the nonhomologous end joining (NHEJ) pathway. b Ratio between the Ku70 protein and 
endogenous GAPDH
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significant difference in the response to treatment with 
PCI-24781 between TP53-proficient and TP53-deficient 
cell lines [35–39]. Dalvai and Bystricky demonstrated that 
the histone hyperacetylation caused by HDAC inhibitors is 
responsible for the antiproliferative effect of the inhibitors, 
which is probably due to specific changes in the expression 
of genes involved in the progression from the G1 to the 
S phase [43]. Several studies have also reported that the 
expression of important proteins involved in the apoptosis 
pathway such as Bad, Bax, caspase 3, caspase 8, Fas, p21, 
TP53 and DR4 was high after treatment with PCI-24781, 
suggesting that this HDACi activates both the intrinsic and 
extrinsic pathways of apoptosis [36, 37, 39, 44].
Regarding the clonogenic capacity, we observed that 
after treatment there was a significant reduction of col-
ony formation in both lines. Several studies have detected 
results similar to those obtained here with PCI-24781 
and various other HDACi in separate or combined treat-
ments of neoplastic cell lines [35, 39, 42].
Clinically, two HDACi inhibitors approved by the FDA, 
suberoylanilide hydroxamic acid (SAHA) and valproic 
acid (VPA), were used in phase I studies conducted on 
children with primary or relapsing CNS tumors. The 
treatments were carried out using the inhibitor alone or 
in combination with chemotherapy and were well toler-
ated in all studies [44–49].
Radiotherapy is an important part of the treatment of 
pediatric GBM. Strategies increasing the efficiency of 
radiotherapy and permitting a reduction of toxic effects 
on normal tissue are important. In this respect, in the 
current study we also investigated the radiosensitizing 
potential of PCI-24781 using clonogenic assays, which 
showed that treatment with the inhibitor significantly 
increased the sensitivity to radiation of both lines.
Other studies have also assessed the radiosensitizing 
effect of PCI-24781 and of other HDACi based on clo-
nogenic capacity in tumors other than GBMs. Chen et al. 
(2009) assessed the radiosensitizing capacity of the HDACi 
VPA on two colon tumor cell lines, one of them with a p53 
mutation and the other without a mutation. The line with 
no TP53 mutation showed a greater reduction of colony 
forming capacity, suggesting that TP53 plays an important 
role in the modulation of the effect of HADCi [50]. Mun-
shi et al. observed an accumulation of acetylation in the H4 
histone after treatment with different HDACi, although 
the radiosensitizing effect on the lines was not influenced 
by this hyperacetylation, with this radiosensitizing mecha-
nism provoked by HDACi being unknown [51].
Fig. 8 PCI-24781 alters the expression of the Ku86 protein. a PCI-24781 reduces the expression of the Ku86 protein, important for the repair of 
double-strand breaks caused by irradiation through the nonhomologous end joining (NHEJ) pathway. b Ratio between the Ku86 protein and 
endogenous GAPDH
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Radiation remains an essential modality in the treat-
ment of various brain tumors. Radiotherapy can be 
delivered alone or in combination with a radiosensitizer 
agent, in order to enhance the efficacy of irradiation. As 
revised by Harasaki and Waziri (2012) [52], the concep-
tual basis for radio sensitization includes at least five 
different mechanisms: spatial cooperation, biologic coop-
eration, cytotoxic enhancement, temporal modulation 
and protection of normal tissues. The number of different 
molecules that may be used concomitant to radiotherapy 
still is evolving. Besides some classical agents in clinical 
use (temozolomide, topotecan, irinotecan, vinka alka-
loids and others), more recently biological modifiers such 
as bevacizumab, lenalidomide, sorafenib, erlotinib and 
dasatinibe have been proposed to display radiosensitizing 
properties for clinical investigation for malignant glioma 
[52]. Many of these compounds (particularly temozolo-
mide and topoisomerase I an II agents) exert their radio-
sensitizer activity via double strand breaks (DSBs). The 
double-strand breaks are the major injuries occurring 
in response to irradiation and their repair is fundamen-
tal in order to determine radiosensitivity. In this respect, 
the HDAC inhibitors specifically target HDACs, a pivotal 
element in the process of condensation and transcrip-
tion of the DNA, abolishing the DNA/protein response 
caused by ionizing radiation. This molecular mechanism 
of action supports the putative role the HDAC inhibi-
tors as potential cytotoxic and radiosensitizing mediators 
[53–56]. Indeed, our study depicted a moderate cytotoxic 
effect of PCI-24781 on cell proliferation and apoptosis, 
particularly at higher drug concentrations. Although 
not contemplated in this study design, the role of PCI-
24781 immediately prior and following to cell irradiation 
deserves further evaluation.
In the present study, in order to validate the radiosen-
sitizing effects observed, we investigated the effect of 
PCI-24781 on the response of the SF188 line in terms of 
the repair of irradiation damage, affecting proteins of two 
important repair pathways, i.e., homologous recombina-
tion (HR) and non-homologous end joining (NHEJ). The 
results showed that PCI-24781 affected the expression of 
important proteins of both the HR pathway (the RAD51 
protein) and of the NHEJ pathway (the KU70, Ku86 and 
DNA-PKcs proteins), leading us to believe that the inhib-
itor proved to be competent in reducing the efficiency of 
the SF188 cell line for the repair of irradiation-induced 
DSB. RAD51 is an important repair protein responsible 
for mediating the search of a homologous DNA sequence 
to be used as a model and for the formation of molecu-
lar joining between the damaged and the undamaged 
Fig. 9 PCI-24781 alters the expression of the DNA-PKcs protein. a PCI-24781 reduces the expression of the DNA-PKcs protein, important for the 
repair of double-strand breaks caused by irradiation through the nonhomologous end joining (NHEJ) pathway. b Ratio between the DNA-PKcs 
protein and endogenous GAPDH
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strands [57]. It has been reported that high expression 
levels of these proteins are related to resistance to radio-
therapy and chemotherapy and therefore low levels of 
these proteins responsible for DSB repair increase the 
radiosensitizing effect of the cells [57–60].
The present study was the first to assess the effect of 
the HDACi PCI-24781 on the expression levels of the 
proteins involved in double-strand DNA repair in pedi-
atric GBM lines.
Previous studies of colon and gastric tumor lines 
and of xenographic models have also observed that the 
level of expression of the RAD51 protein is drastically 
reduced after treatment with PCI-24781, leading to inhi-
bition of DSB repair by homologous recombination [38, 
53, 54]. Several other authors have also investigated the 
radiosensitizing potential of various HADCi in terms of 
their capacity to reduce the repair of damage in differ-
ent tumor lines, significantly reducing the expression of 
RAD51, an important protein for the HR repair pathways 
[53, 61], and of Ku86, Ku70 and DNA-PKcs, important 
proteins for the NHEJ repair pathway [54, 62, 63].
Despite the great interest in combining HDAC inhibi-
tors with radiation as a form of clinical strategy for 
tumor treatment, the exact molecular mechanism of 
the radiosensitizing effect of these inhibitors is still not 
well known. HDAC inhibition facilitates the relaxation 
and opening of chromatin, rendering it more sensitive 
to radiation damage and also modifying the transcrip-
tion of various genes, with these two processes playing 
an important role in the regulation of radiosensitivity. In 
addition, transcriptionally active genes have proved to 
be more sensitive to DNA damage produced by ionizing 
radiation, thus forming a favorable antitumor interaction 
between HDAC inhibitors and radiation. An explanation 
for this increased response to radiation following HDACi 
treatment may be the effect of these inhibitors on the 
DNA repair processes [14, 63–65].
The present study demonstrates that the HDACi PCI-
24781 can reduce the ability of the pediatric GBM line 
to repair radiation-induced DNA damage, increasing the 
radio sensitization of the line.
Conclusion
In conclusion we demonstrated that the HDAC inhibitor 
PCI-24781 reduced proliferation and clonogenic capacity 
and increased apoptosis of pediatric GBM cell lines. In addi-
tion the HDACi PCI-24781 demonstrates high radiosensi-
tizing activity by reducing the capacity of the cells to repair 
Fig. 10 PCI-24781 alters the expression of the RAD51 protein. a PCI-24781 reduces the expression of the RAD51 protein, important for the repair of 
double-strand breaks caused by irradiation through the nonhomologous end joining (NHEJ) pathway. b Ratio between the RAD51 and endog-
enous β-actin
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DNA damage induced by radiation by altering the expres-
sion of nonhomologous proteins (NHEJ). Thus, PCI-24781 
can be considered to be an agent with a good potential for 
studies of in vivo models of pediatric GBM treatment.
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